Psoriasis aggravated by labetalol during pregnancy: a case report

doi:10.19803/j.1672-8629.20220642

Abstract

Abstract: Objective To study the applicability of labetalol hydrochloride tablets in the treatment of gestational hypertension with psoriasis so as to provide reference for safe clinical use of the drug. Methods One case of gestational hypertension with psoriasis aggravated by labetalol hydrochloride tablets in our hospital was analyzed. The mechanism of action and characteristics of skin rash caused by labetalol hydrochloride tablets were explored by referring to literature. Results Labetalol hydrochloride tablets aggravated psoriasis in this patient with hypertension during pregnancy. Conclusion Clinical pharmacists should be sensitive to the adverse drug reactions in the treatment of psoriasis in special populations. Beta-blockers should be used with caution in patients with hypertension complicated with psoriasis during pregnancy.

Key words: labetalol hydrochloride tablets, pregnancy, hypertension, psoriasis, adverse drug reaction

CLC Number:

ZHANG Qing, ZHU Lei, LIN Cunlian, XIE Peitao, YANG Junli, SU Changhai. Psoriasis aggravated by labetalol during pregnancy: a case report[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1060-1063.

References

[1] REGITZ-ZAGROSEK V, ROOS-HESSELINK JW, BAUERSACHS J, et al.2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy[J]. European Heart Journal, 2018, 39(34): 3165-3241.
[2] American College of Obstetricians and Gynecologists. ACOG practice bulletin no.202 gestational hypertension and preeclampsia[J]. Obstet Gynecol, 2019, 133: e1-e25.
[3] HAO H, GU X, CAI Y, et al.The influence of pregnancy-induced hypertension syndrome on the metabolism of newborns[J]. Translational Pediatrics, 2021,10(2): 296-305.
[4] AGRAWAL A, WENGER NK.Hypertension during pregnancy[J]. Current Hypertension Reports, 2020, 22(9): 1-9.
[5] QUINTARD B, CONSTANT A, BOUYSSOU-GAUTHIER ML, et al.Validation of a specific health-related quality of life instrument in a large cohort of patients with psoriasis: the QualiPso Questionnaire[J]. Acta Dermato-Venereologica, 2011, 91(6): 660-665.
[6] AUGUSTIN M, RADTKE MA.Quality of life in psoriasis patients[J]. Expert Review of Pharmacoeconomics & Outcomes Research, 2014, 14(4): 559-568.
[7] BALAK DM, HAJDARBEGOVIC E.Drug-induced psoriasis: clinical perspectives[J]. Psoriasis (Auckland, NZ), 2017, 7: 87-94.
[8] TSANKOV N, ANGELOVA I, KAZANDJIEVA J.Drug-induced psoriasis. recognition and management[J]. American Journal of Clinical Dermatology, 2000, 1(3): 159-165.
[9] BALAK DM, HAJDARBEGOVIC E.Drug-induced psoriasis: clinical perspectives[J]. Psoriasis (Auckl), 2017, 7: 87-94.
[10] GLASS LR, NGUYEN M, WINN BJ, et al.Timolol drops causing reversible psoriatic fingernail changes[J]. JAMA Ophthalmology, 2013, 131(9): 1134.
[11] WAQAR S, SARKAR PK.Exacerbation of psoriasis with beta-blocker therapy[J]. Canadian Medical Association Journal, 2009, 181(1-2): 60.
[12] GANGE RW, JONES EW.Bullous lichen planus caused by labetalol[J]. Br Med J, 1978, 1(6116): 816-817.
[13] FINLAY AY, WADDINGTON E.Cutaneous reactions to labetalol[J]. Br Med J, 1978, 1(6118): 987.
[14] MANCANO MA.Acute generalized exanthematous pustulosis due to labetalol[J]. Hosp Pharm, 2016, 51(6): 437-441.
[15] DIAO YH, LI B, WANG G.Advances in drug studies to induce and aggravate psoriasis[J]. The International Journal of Dermatology and Venereal Diseases(国际皮肤性病学杂志), 2016, 42(4): 219-221.
[16] ZHENG FY, WU Y, RAO YF, et al.The role of the Nobel assessment scale in the adverse drug reaction evaluation and example analysis[J]. Chinese Journal of Pharmacy(中国药学杂志), 2012, 47(8): 650-652.
[17] INGELFINGER FJ.The side effects of aspirin[J]. New England Journal of Medicine, 1974, 290(21): 1196-1197.
[18] CISEN. Instructions-Prednisone acetate tablets[EB/OL]. (2007-05-16)[2020-10-10]. http://ypk.39.net/728677/manual/.
[19] SALVI M,VANNUCCHI G,SBROZZI F, et al.Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report[J]. Thyroid, 2004, 14(8): 631-634.
[20] LI W, ZHENG LL, LI LM, et al.Analysis of adverse reactions of low molecular weight heparin drugs in pregnant women from 2018 to 2020 in a hospital[J]. Jiangxi Medicine(江西医药), 2022, 57(1): 92-94.
[21] ZHANG SS, SONG XF, LI M, et al.Meta-analysis of the association between psoriasis and adverse pregnancy outcomes[J]. The Chinese Journal of Dermatology(中华皮肤科杂志), 2020, 53(4): 299-302.
[22] JOHANSEN CB, EGEBERG A, JIMENEZ-SOLEM E, et al.Psoriasis and adverse pregnancy outcomes: a nationwide case-control study in 491, 274 women in Denmark[J]. JAAD International, 2022, 7: 146-155.
[23] XIE W, HUANG H, JI L, et al.Maternal and neonatal outcomes in pregnant women with psoriasis and psoriatic arthritis: a systematic review and meta-analysis[J]. Rheumatology (Oxford, England), 2021, 60(9): 4018-4028.
[24] WANG W, SUNG N, GILMAN-SACHS A, et al.T helper (th) cell profiles in pregnancy and recurrent pregnancy losses: Th1/Th2/Th9/Th17/Th22/Tfh cells[J]. Frontiers in Immunology, 2020, 11: 2025.
[25] FIGUEIREDO AS, SCHUMACHER A.The T helper type 17/regulatory T cell paradigm in pregnancy[J]. Immunology, 2016, 148(1): 13-21.
[26] SZYMAŃSKA E, KISIELEWSKI R, KIERKUŚ J. Reproduction and pregnancy in inflammatory bowel disease - management and treatment based on current guidelines[J]. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50(3): 101777.
[27] FERREIRA C, AZEVEDO A, NOGUEIRA M, et al. Management of psoriasis in pregnancy - a review of the evidence to date[J]. Drugs Context, 2020, 9: 2019-11-6.
[28] GOTTLIEB AB, MEROLA JF, REICH K, et al.Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from exceed, a randomized, double-blind head-to-head monotherapy study[J]. Br J Dermatol, 2021, 185(6): 1124-1134.
[29] SHI DD, YANG FZ, ZHOU L, et al.Oral nifedipine vs intravenous labetalol for treatment of pregnancy-induced severe preeclampsia[J]. J Clin Pharm Ther, 2016, 41: 657-661.
[30] ACOG. Committee opinion no. 767: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period[J]. Obstet Gynecol, 2019, 133: e174-e180.
[31] ACOG. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222[J]. Obstet Gynecol, 2020, 135: e237-e260.
[32] WU HZ, CHENG Y, YU D, et al.Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials[J]. Hypertension in Pregnancy, 2022, 41(2): 126-138.